Metrikler
Yayın
65
Açık Erişim
13
BM Sürdürülebilir Kalkınma Amaçları
Makaleler
Tümü (60)
SCI-E, SSCI, AHCI (40)
SCI-E, SSCI, AHCI, ESCI (55)
ESCI (15)
Scopus (55)
TRDizin (11)
2025
20251. Real-world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group retrospective study
Ozgun A., Mustafayev F. N. A., Dogan I., Vatansever S., Eryilmaz M. K., ERDOĞAN A. P., et al.
Molecular and Clinical Oncology
, cilt.22, sa.6, 2025 (ESCI)
2025
20252. Clinical factors predicting objective response to bevacizumab-based chemotherapies in advanced and recurrent epithelial ovarian cancer
Khanmammadov N., Dogan I., Okay N. S., KHISHIGSUREN B., AZİZY A., Saip P., et al.
Minerva obstetrics and gynecology
, cilt.77, sa.2, ss.112-118, 2025 (ESCI)
2025
20253. The efficacy of second-line chemotherapy in the management of classic and iatrogenic Kaposi sarcoma: An analysis of real-world data
Khanmammadov N., Ferhatoglu F., PAKSOY N., Dogan İ., KHISHIGSUREN B., Nizam N., et al.
Medicine (United States)
, cilt.104, sa.6, 2025 (SCI-Expanded)
2025
20254. Rechallenge of trastuzumab-based therapy in HER2-positive breast cancer patients who progressed after lapatinib plus capecitabine
Khanmammadov N., Doǧan I., KHISHIGSUREN B., AZİZY A., Saip P., AYDINER A.
Medicine (United States)
, cilt.104, sa.6, 2025 (SCI-Expanded)
2024
20245. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases
Kahraman S., Karakaya S., Kaplan M. A., SEZGİN GÖKSU S., Ozturk A., Isleyen Z. S., et al.
Scientific Reports
, cilt.14, sa.1, 2024 (SCI-Expanded)
2024
20246. Efficacy of Lapatinib Plus Capecitabine After TDM-1 in HER2-Positive Metastatic Breast Cancer Patients
Dogan I., Yıldız A., Ahmed M. A., Vatansever S.
Indian Journal of Surgical Oncology
, cilt.15, sa.3, ss.489-494, 2024 (ESCI)
2024
20247. Rechallenge of Trastuzumab-based Therapy in HER2-Positive Breast Cancer Patients who Progressed Under TDM-1
Dogan I., AHMED M. A., YILDIZ A., Vatansever S.
INDIAN JOURNAL OF SURGICAL ONCOLOGY
, sa.3, ss.484-488, 2024 (ESCI)
2024
20248. Efficacy of Bevacizumab-Based Terapy in Patient With Metastatic or Recurrent Cervical Cancer: Real Life Data
KHANMAMMADOV N., Dogan I., okay n. s., Ugar M., Osmanova N., Saip P., et al.
Selçuk Tıp Dergisi
, cilt.40, sa.2, ss.68-73, 2024 (Hakemli Dergi)
2024
20249. Hormonal Therapy in Pretreated Patients With Recurrent Ovary Granulosa Cell Tumor
DOĞAN İ., Aydın E., Topuz S., Saip P., Salihoglu M. Y., Aydiner A.
JOURNAL OF PHARMACY PRACTICE
, cilt.37, sa.1, ss.146-150, 2024 (ESCI)
2024
202410. Comparative analysis of doublet chemotherapy regimens plus bevacizumab in patients with recurrent ovarian cancer
Khanmammadov N., Doǧan I., Okay N. S., AZİZY A., Saip P., AYDINER A.
Medicine (United States)
, cilt.103, sa.1, 2024 (SCI-Expanded)
2024
202411. Evaluation of the Efficacy of Bevacizumab-based Therapies in Patients with Platinum-Resistant or-Allergic Metastatic Ovarian Cancer
Khanmammadov N., Doğan İ., Okay N. S., YILDIZ A., Khishigsuren B., AZİZY A., et al.
Turk Onkoloji Dergisi
, cilt.39, sa.2, ss.176-182, 2024 (ESCI)
2024
202412. Efficacy and safety of sorafenib in adult metastatic osteosarcoma patients
Dogan I., PAKSOY N., BAŞARAN M.
Journal of Cancer Research and Therapeutics
, cilt.20, sa.3, ss.979-983, 2024 (SCI-Expanded)
2024
202413. The Effect of Adjuvant Therapies for Recurrence in Stage I Breast Cancer Patients: A Single Centre Experience
Doğan İ., Khanmammadov N., Aydin E., PAKSOY N., Ferhatoğlu F., AK N., et al.
Turk Onkoloji Dergisi
, cilt.39, sa.3, ss.257-264, 2024 (ESCI, Scopus, TRDizin)
2024
202414. Single-agent temozolomide as salvage therapy in heavily pretreated metastatic sarcoma patients
Dogan I., Paksoy N., BAŞARAN M.
Journal of Cancer Research and Therapeutics
, cilt.20, sa.1, ss.93-97, 2024 (SCI-Expanded)
2024
202415. Outcomes of the patients with metastatic male breast cancer
Dogan I., Khanmammadov N., ÖZKURT S., AYDINER A., Saip P.
Journal of Cancer Research and Therapeutics
, cilt.20, sa.1, ss.98-102, 2024 (SCI-Expanded)
2024
202416. The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics of breast cancer patients
Ak N., Tuz Z., Aydin E., Ferhatoğlu F., SARI M., Paksoy N., et al.
Turkish Journal of Medical Sciences
, cilt.54, sa.1, ss.229-238, 2024 (SCI-Expanded, Scopus, TRDizin)
2024
202417. Efficacy of Intrathecal Therapy In Breast Cancer Patients With Leptomeningeal Metastasis
Khanmammadov N., Dogan I., AHMED M. A., YILDIZ A., Nizam N., KHISHIGSUREN B., et al.
Eastern Journal of Medicine
, cilt.29, sa.4, ss.503-508, 2024 (Scopus)
2023
202318. Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Saip P., AYDINER A.
Scientific Reports
, cilt.13, sa.1, 2023 (SCI-Expanded)
2023
202319. Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients
DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Ferhatoğlu F., AK N., et al.
Journal of Cancer Research and Clinical Oncology
, cilt.149, sa.16, ss.14833-14841, 2023 (SCI-Expanded, Scopus)
2023
202320. Efficacy and outcomes of systemic chemotherapy in posttransplant and immunosuppression associated Kaposi sarcoma: Twenty years experience of a tertiary cancer center
Khanmammadov N. A., Paksoy N., DOĞAN İ., Ferhatoğlu F., Saip P., Aydiner A.
Medicine
, cilt.102, sa.39, 2023 (SCI-Expanded)
2023
202321. Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors
DOĞAN İ., KHANMAMMADOV N., PAKSOY N., VATANSEVER S., SAİP P., AYDINER A.
Eurasian Journal of Pulmonology
, cilt.25, sa.1, ss.27-32, 2023 (Hakemli Dergi)
2023
202322. Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine
DOĞAN İ., Paksoy N., AK N., VATANSEVER S., Saip P., AYDINER A.
European Journal of Breast Health
, cilt.19, sa.2, ss.128-133, 2023 (Scopus)
2023
202323. Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group
DOĞAN İ., AKSOY S., Cakar B., BAŞARAN G., Ercelep O., Molinas Mandel N., et al.
Cancers
, cilt.15, sa.6, 2023 (SCI-Expanded)
2023
202324. Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study
Paksoy N., KHANMAMMADOV N., DOĞAN İ., Ferhatoǧlu F., AHMED M. A., Karaman S., et al.
Medicine (Spain)
, cilt.102, sa.5, 2023 (Scopus)
2023
202325. Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma
DOĞAN İ., Iribas A., Ahmed M. A., Basaran M.
JOURNAL OF CHEMOTHERAPY
, cilt.35, sa.4, ss.343-347, 2023 (SCI-Expanded)
2023
202326. Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience
TAŞTEKİN D., Paksoy N., DOĞAN İ., Ferhatoglu F., KHANMAMMADOV N., Bozbey H. U., et al.
Journal of cancer research and therapeutics
, cilt.19, sa.2, ss.253-258, 2023 (SCI-Expanded)
2023
202327. Clinicopathologic characteristics and prognostic factors in patients with male breast cancer: A single tertiary center experience
Dogan I., AYDIN E., AK N., ÖZKURT S., İBİŞ K., ŞÜKRÜOĞLU ERDOĞAN Ö., et al.
Journal of Cancer Research and Therapeutics
, cilt.19, sa.7, ss.1887-1892, 2023 (SCI-Expanded, Scopus)
2022
202228. High-dose chemotherapy followed by autologous stem cell transplantation for adult patients with first relapse of Ewing's sarcoma: A single institution experience
PAKSOY N., FERHATOĞLU F., DOĞAN İ., KHANMAMMADOV N., Iribas Celik A., Gulbas Z., et al.
Medicine (United States)
, cilt.101, sa.49, 2022 (SCI-Expanded)
2022
202229. Systemic Immune-Inflammation Index as a Prognostic Marker of Late Recurrence in Operable Gastric Cancer: a Dual-Center Study
Yekeduz E., Dogan I., Kaya D. M., Ozgur I., UTKAN G., Vatansever S., et al.
JOURNAL OF GASTROINTESTINAL CANCER
, cilt.53, sa.4, ss.870-879, 2022 (ESCI)
2022
202230. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group
Erol C., Nahit Sendur M. A., Bilgetekin I., Garbioglu D. B., Hamdard J., Akbas S., et al.
Journal of cancer research and therapeutics
, cilt.18, 2022 (SCI-Expanded)
2022
202231. Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study
PAKSOY N., KHANMAMMADOV N., DOĞAN İ., FERHATOĞLU F., YILDIZ A., AK N., et al.
Medicine (United States)
, cilt.101, sa.45, 2022 (SCI-Expanded)
2022
202232. Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients
DOĞAN İ., Aydin E., Yazici H., Saip P.
EUROPEAN JOURNAL OF BREAST HEALTH
, cilt.18, sa.4, ss.323-328, 2022 (ESCI)
2022
202233. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study
Dogan I., Ayhan M., Gurbuz M., Kucukarda A., Aydın E., ÜRÜN Y., et al.
MEDICINE
, cilt.101, sa.35, 2022 (SCI-Expanded)
2022
202234. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study
Ozdemir O., Zengel B., Yildiz Y., Uluc B. O., ÇABUK D., Ozden E., et al.
ANTI-CANCER DRUGS
, cilt.33, sa.7, ss.663-670, 2022 (SCI-Expanded)
2022
202235. Capecitabine and temozolomide (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors
DOĞAN İ., Tastekin D., Karabulut S., Sakar B.
JOURNAL OF DIGESTIVE DISEASES
, cilt.23, ss.493-499, 2022 (SCI-Expanded)
2022
202236. Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer
DOĞAN İ., Karabulut S., Tastekin D., Ferhatoglu F., Paksoy N., Sakar B.
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN
, cilt.32, sa.8, ss.1014-1019, 2022 (SCI-Expanded)
2022
202237. Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC
DOĞAN İ., Gurbuz M., Paksoy N., Ferhatoglu F., Vatansever S., Saip P., et al.
MEDICINE
, cilt.101, sa.34, 2022 (SCI-Expanded)
2022
202238. Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib
DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., et al.
CLINICAL CANCER INVESTIGATION JOURNAL
, sa.4, ss.5-9, 2022 (ESCI)
2022
202239. Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.
Dogan I., Paksoy N., Ak N., Vatansever S., Saip P., Aydiner A.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.40, sa.16, 2022 (SCI-Expanded)
2022
202240. Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience
DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., et al.
CLINICAL CANCER INVESTIGATION JOURNAL
, sa.3, ss.25-29, 2022 (ESCI)
2022
202241. The relationship between clinicopathological parameters and PD-L1 expression level in advanced stage non-small cell lung cancer
Gurbuz M., DOĞAN İ., AKKUŞ E., ÖZAKINCI H., Tolunay P. K., KALACI E., et al.
TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX
, cilt.70, sa.2, ss.132-140, 2022 (ESCI)
2022
202242. Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study
Paksoy N., Ferhatoglu F., DOĞAN İ., Khanmammadov N., Bozbey H. U., KARABULUT S., et al.
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
, cilt.37, sa.4, ss.478-483, 2022 (ESCI)
2022
202243. Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib
Dogan I., Khanmammadov N., Paksoy N., Ferhatoglu F., Aydın E., Vatansever S., et al.
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
, cilt.37, ss.413-418, 2022 (ESCI)
2022
202244. Prognostic value of FDG PET-CT in suspected recurrence of colorectal carcinoma: survival outcomes of a 10-year follow-up : FDG PET in recurrent colorectal CA.
ozkan Z. G., Has Simsek D., Kuyumcu S., Oflas M., Isik E. G., Dogan I., et al.
Annals of nuclear medicine
, cilt.36, sa.1, ss.52-60, 2022 (SCI-Expanded, Scopus)
2022
202245. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer
Ay S., Atci M. M., Arikan R., Dulgar O., Ozyukseler D. T., Paksoy N., et al.
JOURNAL OF CHEMOTHERAPY
, cilt.34, sa.7, ss.465-471, 2022 (SCI-Expanded)
2022
202246. Does nutritional status affect treatment tolerability, chemotherapy response and survival in metastatic gastric cancer patients? Results of a prospective multicenter study in Turkey
Karabulut S., DOĞAN İ., USUL AFŞAR Ç., Karabulut M., Ak N., Duran A., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
, cilt.28, sa.1, ss.127-134, 2022 (SCI-Expanded)
2021
202147. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study
Bilgin B., Sendur M. A. N., Yucel S., Celik E., Ozyukseler D. T., Ayhan M., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
, cilt.147, sa.7, ss.2145-2152, 2021 (SCI-Expanded)
2021
202148. Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors.
Ferhatoglu F., Paksoy N., Dogan I., Ak N., Pehlivan M., Ekenel M., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.39, sa.15, 2021 (SCI-Expanded)
2021
202149. Efficacy of vincristine, irinotecan, and temozolomide (VIT) combination in adult patients with metastatic Ewing sarcoma.
Dogan I., Iribas A., Ekenel M., Basaran M.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.39, sa.15, 2021 (SCI-Expanded)
2021
202150. Efficacy of temozolomide in pretreated patients with metastatic sarcoma.
Paksoy N., Dogan I., Ekenel M., Basaran M.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.39, sa.15, 2021 (SCI-Expanded)
2021
202151. Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma.
Paksoy N., Dogan I., Ekenel M., Basaran M.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.39, sa.15, 2021 (SCI-Expanded)
2021
202152. Long-term outcomes and predictors of recurrence in patients with early-stage node negative breast cancer.
Dogan I., Aydin E., Paksoy N., Ferhatoglu F., Ak N., Ibis K., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.39, sa.15, 2021 (SCI-Expanded, Scopus)
2021
202153. Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors.
Aydiner A., Dogan I., Khanmammadov N., Saip P., Vatansever S.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.39, sa.15, 2021 (SCI-Expanded)
2021
202154. Termination of trastuzumab-based treatment after complete response in HER2-positive metastatic breast cancer
Dogan I., Aydin E., Khanmammadov N., Aydiner A., Saip P.
CANCER RESEARCH
, cilt.81, sa.4, 2021 (SCI-Expanded)
2021
202155. Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases.
Dogan I., Iribas A., Paksoy N., Ekenel M., Vatansever S., Basaran M.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.39, sa.6, 2021 (SCI-Expanded)
2021
202156. Outcomes of metastatic male breast cancer
Dogan I., Khanmammadov N., Aydiner A., Saip P.
CANCER RESEARCH
, cilt.81, sa.4, 2021 (SCI-Expanded)
2021
202157. Comparison of clinicopathological features in BRCA-wild type and -mutated male breast cancer patients
Dogan I., Aydin E., Yazici H., Saip P.
CANCER RESEARCH
, cilt.81, sa.4, 2021 (SCI-Expanded)
2021
202158. Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma
Naziye A. K., Paksoy N., Ferhatoglu F., Aydin E., Dogan I., Bektas E., et al.
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
, cilt.36, ss.438-445, 2021 (ESCI)
2021
202159. Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.
Dogan I., Tastekin D., Karabulut S., Sakar B.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.39, sa.3, 2021 (SCI-Expanded)
2021
202160. A retrospective multicenter study: Clinicopathological factors affecting recurrence-free survival in operable gastric cancer patients.
Yekeduz E., Dogan I., AKBULUT H., Karabulut S., Utkan G., ÜRÜN Y.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.39, sa.3, 2021 (SCI-Expanded)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2023
20231. Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer.
Khanmammadov N., DOĞAN İ., Saip P., Aydiner A.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 06 Haziran 2023, (Özet Bildiri)
2020
20202. iRECIST, irRC and irRECIST: A Pairwise Agreement and Performance Evaluation Study
Kızıldağ Yırgın İ., Doğan İ., Vatansever S., Ertürk Ş. M.
RSNA2020, Illinois, Amerika Birleşik Devletleri, 24 - 29 Kasım 2020, ss.988, (Tam Metin Bildiri)
2020
20203. Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma
Gurbuz M., DOĞAN İ., Utkan G., TAŞ F.
ESMO Asia Virtual Congress, ELECTR NETWORK, 20 - 22 Kasım 2020, cilt.31, (Özet Bildiri)
2020
20204. Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience
DOĞAN İ., AYDIN E. M., AK N., İBİŞ K., Sukruoglu Ö., Erciyas S., et al.
ESMO Asia Virtual Congress, ELECTR NETWORK, 20 - 22 Kasım 2020, cilt.31, (Özet Bildiri)
2020
20205. BAĞIŞIKLIK KONTROL NOKTASI İNHİBİTÖRLERİ: İRECIST, İRRC VE İRRECIST’İN PERFORMANSLARININ VE UYUMLARININ DEĞERLENDİRİLMESİ IMMUNE CHECKPOİNT İNHİBİTORS: ASSESSMENT OF THE PERFORMANCE AND THE AGREEMENT OF İRECIST, İRRC AND İRRECIST
Kızıldağ Yırgın İ., Doğan İ., Vatansever S., Ertürk Ş. M.
41.Ulusal Radyoloji Kongresi, Antalya, Türkiye, 24 Ekim - 01 Kasım 2020, ss.205-206, (Tam Metin Bildiri)